SPECIAL ISSUE - RESEARCH ARTICLE

Studies on the in vivo metabolism of methylstenbolone and detection of novel long term metabolites for doping control analysis

Thomas Piper1 | Gregor Fusshöller1 | Wilhelm Schänzer1 | Andreas Lagojda2 | Dirk Kuehne2 | Mario Thevis1,3

1Center for Preventive Doping Research, German Sport University Cologne, Cologne, Germany
2Crop Science Division, Bayer AG, Monheim, Germany
3European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany

Correspondence
Thomas Piper, German Sport University Cologne, Center for Preventive Doping Research, Am Sportpark Münstersdorf 650933, Cologne, Germany.
Email: t.piper@biochem.dshs-koeln.de

Funding information
Federal Ministry of the Interior, Building and Community (Berlin, Germany); Manfred-Donike Institute for Doping Analysis (Cologne, Germany)

Abstract
The anabolic-androgenic steroid methylstenbolone (MSTEN; 2α,17α-dimethyl-17β-hydroxy-5α-androst-1-en-3-one) is available as a so-called designer steroid or nutritional supplement. It is occasionally detected in doping control samples, predominantly tested and confirmed as the glucuronic acid conjugate of methylstenbolone. The absence of other meaningful metabolites reported as target analytes for sports drug testing purposes can be explained by the advertised metabolic stability of methylstenbolone. In 2013, a first investigation into the human metabolism of methylstenbolone was published, and two hydroxylated metabolites were identified as potential targets for initial testing procedures in doping controls. These metabolites were not observed in recent doping control samples that yielded adverse analytical findings for methylstenbolone, and in the light of additional data originating from a recent publication on the in vivo metabolism of methylstenbolone in the horse, revisiting the metabolic reactions in humans appeared warranted. Therefore, deuterated methylstenbolone together with hydrogen isotope ratio mass spectrometry (IRMS) in combination with high accuracy/high resolution mass spectrometry were employed. After oral administration of a single dose of 10 mg of doubly labeled methylstenbolone, urine samples were collected for 29 days. Up to 40 different deuterated methylstenbolone metabolites were detected in post-administration samples, predominantly as glucuronic acid conjugates, and all were investigated regarding their potential to prolong the detection window for doping controls. Besides methylstenbolone excreted glucuronidated, three additional metabolites were still detectable at the end of the study on day 29. The most promising candidates for inclusion into routine sports drug testing methods (2α,17α-dimethyl-5α-androst-1-ene-3β,17β-diol and 2α,17α-dimethyl-5α-androst-1-ene-3α,17β-diol) were synthesized and characterized by NMR.

Received: 15 August 2019 | Revised: 31 October 2019 | Accepted: 10 November 2019
DOI: 10.1002/dta.2736

© 2019 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd

1644 | wileyonlinelibrary.com/journal/dta

Drug Test Anal. 2019;11:1644–1655.
**INTRODUCTION**

Anabolic-androgenic steroids such as methylstenbolone (MSTEN; 2α,17α-dimethyl-17β-hydroxy-5α-androst-1-en-3-one) are prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA).\(^1\) Despite an increasing number of antidoping legislations in numerous countries, a decrease in the trafficking of steroidal drugs (as well as other doping agents) has been barely noticeable and they are readily available via the world wide web. For many years, anabolic agents have been among the most frequently detected banned substances in sport.\(^2\)

In doping control analysis, the targeting of urinary metabolites of administered compounds is frequently the superior strategy over detecting the intact and unmodified compound itself. Therefore, comprehensive investigations of phase-I- and phase-II-metabolic reactions of doping agents have contributed to improved detectability in numerous cases.

Regarding methylstenbolone, so far only one study has reported on human in vivo metabolism, and two hydroxylated urinary metabolites have been described.\(^3\) Both metabolites were detectable in urine for a longer time period (up to 7 days) than methylstenbolone itself. These results, however, did not reflect recent findings in doping control samples in which MSTEN glucuronide but not the reported hydroxylated metabolites were detected. Also, additional hydroxylated metabolites identified in in vitro and humanized mouse metabolism studies on methylstenbolone are not directly applicable to sports drug testing.\(^4\) In a recent investigation focusing on the metabolism of methylstenbolone in the horse, several metabolites were described that were detectable for a longer time period than methylstenbolone itself.\(^5\) Based on these results, revisiting the metabolism of methylstenbolone in humans seemed advisable in order to elucidate the discrepancies found between the described and observed urinary metabolites and to facilitate the improved detection of this banned steroid in doping control analysis.

In order to generate a comprehensive profile of urinary methylstenbolone metabolites, a recently established approach utilizing hydrogen isotope ratio (HIR) determinations was applied.\(^6\)–\(^9\) Therefore, two-fold deuterated MSTEN was administered to one healthy male volunteer, and the collected urine samples were processed and analyzed using gas chromatography/thermal conversion/isotope ratio mass spectrometry (GC/TC/IRMS) to detect urinary steroids comprising at least one deuterium atom. All identified metabolites were further analyzed by gas chromatography/high resolution-high accuracy/mass spectrometry (GC–HRMS) to validate their deuterium content and to elucidate their structural characteristics.

Promising metabolite candidates were investigated regarding their potential to improve and prolong the traceability of methylstenbolone administration. In order to corroborate the utility of newly identified metabolites for doping control, an excretion study was conducted using unlabeled methylstenbolone, and urine samples were analyzed under authentic routine sports drug testing conditions, complemented by the herein discovered, synthesized, and additionally NMR-characterized metabolites.

**EXPERIMENTAL**

### 2.1 Reagents and chemicals

Pyridine, glacial acetic acid, sodium hydroxide, methanol, sulfuric acid, acetonitrile (ACN), tert-butyl methyl ether (TBME), and cyclohexane were purchased from Merck (Darmstadt, Germany). Acetic anhydride was from Fluka/Sigma-Aldrich (Steinheim, Germany). N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA) was purchased from Chemische Fabrik Karl Bucher (Waldstetten, Germany). All reagents and chemicals were of analytical grade. β-Glucuronidase from *Escherichia coli* was from Roche Diagnostics GmbH (Mannheim, Germany).

Deuterated MSTEN (4,4-D\(^2\)-H\(_2\)-MSTEN, chemical purity >98%) was synthesized and purified by high performance liquid chromatography (HPLC) in-house employing established protocols.\(^10\),\(^11\) Non-deuterated methylstenbolone was purchased from Toronto Research Chemicals (North York, ON, Canada). Methasterone (2α,17α-dimethyl-5α-androstan-17β-ol-3-one) was from Steraloids (Newport, RI, USA) and lithium aluminum hydride (LiAlH\(_4\)) was from Sigma (Deisendorf, Germany).

### 2.2 Elimination studies

Deuterated methylstenbolone was administered orally (10 mg, dissolved in ethanol/water 30/70 v/v) to one healthy male volunteer (43 years old, 180 cm tall with a weight of 84 kg) who declared not to have used any nutritional supplements or medication for at least 4 weeks prior to this study. Three blank morning urine samples were collected on the days before administration, followed by the collection of all urine samples during the first 48 h. Additionally, all morning urines were sampled until day 6 post-administration, followed by one morning urine sample every other day until day 29.

Six months later, the same volunteer orally administered 20 mg of non-deuterated MSTEN, again dissolved in ethanol/water 30/
2.3 | Sample preparation for HIR determinations

The different steps in the sample preparation for all specimens collected during the elimination study with deuterated MSTEN are described in detail elsewhere. In brief, 20 mL of urine was applied onto a preconditioned solid-phase extraction (SPE) cartridge (Chromabond® C18, Macherey-Nagel, Düren, Germany), washed with water, and eluted with methanol. After evaporation, the dried residue was reconstituted in 2 mL of aqueous phosphate buffer (pH 7) and extracted with tert-butyl methyl ether to yield the unconjugated steroid fraction. To the aqueous residue, β-glucuronidase was added, and after 60 min at 50°C, an aqueous potassium carbonate buffer (pH 10) was added to allow for partitioning of the formerly glucuronidated steroids into tert-butyl methyl ether. The aqueous layer is subsequently acidified and applied onto another SPE cartridge followed by acidic solvolysis, employing sulfuric acid in ethyl acetate. Finally, the formerly sulfocojugated steroids were extracted.

The fraction of unconjugated steroids was immediately forwarded to hydrogen isotope ratio determinations while the formerly glucuronidated and sulfated steroids were subjected to high performance liquid chromatographic clean-up. This was accomplished using an Agilent 1100 HPLC system (Waldbronn, Germany) equipped with a XBridge™ Shield RP18 5 mm (4.6 × 250 mm) column, protected by a XBridge™ Shield RP18 5 mm (4.6 × 20 mm) guard column from Waters (Eschborn, Germany). Solvents used for gradient elution were: A: water and B: acetonitrile. The gradient started from 20% acetonitrile, increased to 100% acetonitrile within 25 min and was held for 5 min followed by re-equilibration for 5 min at 20% acetonitrile. The flow was set to 1 mL/min and the injection volume was 100 μL. Fractions were collected using a FOXY R1 automatic fraction collector (Axel Semrau, Sprockhövel, Germany) from 4.00 to 10.00, from 10.01 to 13.00, from 13.01 to 16.00, from 16.01 to 18.00, from 18.01 to 20.00, from 20.01 to 24.00, and from 24.01 to 30.00 min.

All fractions were evaporated and trimethylsilylated using N-methyl-N-trimethylsilyl trifluoroacetamide in ethyl acetate (20/80, v/v) at 70°C for 45 min. After evaporation, the samples were transferred into auto-sampler vials using 200 μL of ethyl acetate, dried in a desiccator, and reconstituted as necessary for IRMS or HRMS determinations.

2.4 | Gas chromatography/isotope ratio mass spectrometry setup

The instrumentation used for all HIR determinations was a Delta V Plus IRMS (Thermo Fisher Scientific, Bremen, Germany) coupled to a Trace GC 1310 equipped with a TriPlusRSH autosampler via the GC IsoLink CNH and the ConFlow IV (all Thermo). The thermal conversion ceramic tubing (320 mm length, 0.5 mm inner diameter, 1.5 mm outer diameter from IVA Analysentechnik, Meerbusch, Germany) was operated at 1450°C for pyrolysis. The IRMS was hyphenated to an ISQ mass spectrometer (Thermo) operated in positive electron ionization mode recording total ion chromatograms from m/z 50 to 800.

The GC column used was a HP-Ultra 1 column (length 17 m, i.d. 0.2 mm, film thickness 0.11 μm) from Agilent (Waldbronn, Germany). The temperature program started at 100°C was held for 2 min, then with 30°C/min to 184°C, then with 6°C/min to the final temperature of 310°C which was held for 3.5 min. Injections were done in splitless mode at 300°C using the programmed flow option starting with 4 mL/min of helium (purity 5.0), held for 1.5 min and then changed with a speed of 10 mL/min to 1.2 mL/min for the analytical run. The injection volume was 4 μL of ethyl acetate. Data were acquired using either Isodat 3.0 or Xcalibur 2.2 (both Thermo).

2.5 | Gas chromatography/high resolution mass spectrometry

In order to presumably identify the structure and the deuterium content of the detected metabolites, all HIR samples were diluted by a factor of 5 to 20 and re-injected on an Agilent 7200 Accurate-Mass Q-TOF system coupled to an Agilent 7890A gas chromatograph (Santa Clara, CA). The GC column and parameters were equivalent to those described above, the injection volume was reduced to 2 μL and the pulsed splitless option was chosen with an initial pressure of 40 psi. Data covering a scan range from m/z 50 to 800 with a scan speed of 333 ms/spectrum were acquired and evaluated using MassHunter software (version B.06, Agilent). The instrument was mass calibrated prior to each sequence in order to achieve mass accuracy in the range of ±5 ppm.

Additional studies to improve the identification and detectability of those metabolites important for doping control analysis were conducted on a Q Exactive GC Orbitrap GC–MS/MS system (Thermo) under routine doping control conditions. In a first step, selected samples were re-prepared as described above employing the HPLC clean-up but subsequently derivatized using MSTFA/NH4I/ethanethiol 1000:2:3 (v:v:v). Finally, sample preparation was conducted according to routine analytical conditions to demonstrate the feasibility of directly implementing the most promising target analytes. Also, the GC was equipped with a HP-Ultra 1 analytical column, but the temperature program was slightly different. The initial temperature of 180°C was increased with 3°C/min to 240°C and then with
40°C/min to 320°C and held for 2 min. Injections were performed in split mode at 300°C with a split and purge flow of 5 mL/min each. A constant flow was set to 1 mL/min and transfer line temperatures were at 280 and 300°C. Data were acquired in full MS mode covering a scan range of m/z 50 to 700 or in parallel reaction monitoring using an isolation window of m/z 1.3. The resolution was set to 60,000 and data were evaluated using Xcalibur (Version 4.0, Thermo). Daily mass calibration of the instrument yielded mass accuracy in the range of ±2 ppm.

2.6 | Synthesis of the new long-term metabolite

Ten milligrams of methylstenbolone was dissolved in 2 mL of tetrahydrofuran (THF). Then, 200 μL of a solution of lithium aluminum hydride (1 M in THF) was added dropwise. The mixture was vortexed and after 10 min at room temperature, 5 mL of water was added and the reaction products were liquid–liquid-extracted twice using 5 mL of TBME. After evaporation, the dried residue was reconstituted in 2 mL of acetonitrile/water (50/50) and forwarded to HPLC clean-up on the above mentioned system. The employed gradient was modified to start with 60% acetonitrile, increasing to 80% acetonitrile in 10 min, then to 100% acetonitrile in 0.1 min, where it was held for 5 min prior to re-equilibration for 5 min at starting conditions. The injection volume was reduced to 50 μL to prevent column overload. In addition to the fraction containing methylstenbolone (collection window from 8.21 to 9.00 min), two fractions containing metabolites were collected (from 7.10 min to 7.70 min and from 7.71 min to 8.20 min) and forwarded to nuclear magnetic resonance (NMR) spectroscopy.

2.7 | Nuclear magnetic resonance spectroscopy

Prior to NMR analysis, the reduced methylstenbolone products were subjected to another LC fractionation step using an Agilent (Waldbronn, Germany) 1100 Series HPLC equipped with a Macherey-Nagel (Düren, Germany) Nucleodur C18 Gravity column (250 × 4.0 mm, 5 μm particle size). The eluents used were 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). Gradient elution was conducted starting at 20% B for 1 min, increasing to 95% B within 25 min, maintaining 95% B for 10 min followed by re-equilibration at 0% B. The flow rate of 1 mL/min was directed to an Agilent 1260 fraction collector (Waldbronn, Germany). Time-based fractions of 6 s were collected. The assessment of the fractions by LC/HRMS was performed on a Q Exactive mass spectrometer (Thermo, Bremen, Germany). The substance of interest was detected at a retention time at 17.50 min and five fractions at 6 s were collected. The fractions were dried in a vacuum concentrator,
The sample was dissolved and transferred into the NMR tube using 50 μL of deuterated chloroform (CDCl₃). To address the analytical questions, ¹³C, ¹H, ¹H,¹H-COSY, ¹³C-¹H-HSQC, ¹³C-¹H-HMBC, and NOESY experiments were conducted utilizing a Bruker Avance NEO 800 MHz NMR spectrometer (Bruker, Karlsruhe, Germany).

### TABLE 1

| Consecutive number | HPLC fraction | Retention time | Accurate mass [m/z] | Elemental composition | Mass error [ppm] |
|--------------------|---------------|----------------|---------------------|-----------------------|------------------|
| 1                  | G_I           | 13.4           | 326.2062            | C₁₇H₃₀D₂O₂Si₂        | 0.3              |
| 2                  |               | 19.5           | 563.3414            | C₂₀H₄₂D₂O₂Si₃        | 4.9              |
| 3                  | G_II          | 16.0           | 549.3608            | C₂₀H₄₂D₂O₂Si₃        | 2.5              |
| 4                  |               | 17.3           | 449.3235            | C₂₀H₄₂D₂O₂Si₂        | 0.1              |
| 5                  |               | 17.4           | 549.3607            | C₂₀H₄₂D₂O₂Si₂        | 2.3              |
| 6                  |               | 17.6           | 449.3236            | C₂₀H₄₂D₂O₂Si₂        | 0.3              |
| 7                  |               | 18.3           | 549.3611            | C₂₀H₄₂D₂O₂Si₂        | 2.9              |
| 8*                 | G_III         | 12.1           | 395.2794            | C₁₈H₃₄D₂O₂Si₂        | −0.7             |
| 9                  |               | 13.6           | 475.2487            | C₂₀H₄₂D₂O₂Si₂        | 0.7              |
| 10                 |               | 16.1           | 339.2136            | C₁₈H₃₄D₂O₂Si₂        | −0.8             |
| 11*                |               | 17.1           | 550.3665            | C₂₀H₄₂D₂O₂Si₂        | 1.5              |
| 12*                |               | 17.9           | 552.3831            | C₂₀H₄₂D₂O₂Si₂        | 3.1              |
| 13                 |               | 18.1           | 549.3613            | C₂₀H₄₂D₂O₂Si₂        | 3.3              |
| 14                 |               | 18.9           | 549.3611            | C₂₀H₄₂D₂O₂Si₂        | 2.9              |
| 15                 |               | 19.9           | 547.3449            | C₂₀H₄₂D₂O₂Si₂        | 2.1              |
| 16                 | G_IV          | 16.5           | 549.3609            | C₂₀H₄₂D₂O₂Si₂        | 2.7              |
| 17                 |               | 17.0           | 549.3608            | C₂₀H₄₂D₂O₂Si₂        | 2.4              |
| 18                 |               | 19.4           | 552.3848            | C₂₀H₄₂D₂O₂Si₂        | 6.2              |
| 19                 |               | 21.6           | 551.3752            | C₂₀H₄₂D₂O₂Si₂        | 0.2              |
| 20                 | G_V           | 10.7           | 461.325             | C₂₂H₃₄D₂O₂Si₂        | −0.1             |
| 21*                |               | 12.9           | 464.3464            | C₂₂H₃₄D₂O₂Si₂        | −1.1             |
| 22*                |               | 14.0           | 461.3253            | C₂₂H₃₄D₂O₂Si₂        | 0.5              |
| 23*                |               | 14.2           | 464.3464            | C₂₂H₃₄D₂O₂Si₂        | −1.2             |
| 24                 |               | 14.3           | 387.2698            | C₂₂H₃₄D₂O₂Si₂        | −0.1             |
| 25                 |               | 19.5           | 463.3392            | C₂₂H₃₄D₂O₂Si₂        | −3.2             |
| 26*                | S_III         | 12.0           | 395.2797            | C₁₈H₃₄D₂O₂Si₂        | 0.1              |
| 27                 |               | 14.0           | 217.1917            | C₁₈H₃₄D₂O₂Si₂        | −1.5             |
| 28                 |               | 14.3           | 320.2496            | C₂₀H₄₂D₂O₃Si        | −0.9             |
| 29                 |               | 15.4           | 339.2136            | C₁₈H₃₄D₂O₂Si₂        | −0.9             |
| 30                 |               | 16.8           | 552.3832            | C₂₀H₄₂D₂O₂Si₂        | 3.3              |
| 31*                |               | 17.1           | 550.3674            | C₂₀H₄₂D₂O₂Si₂        | 0.2              |
| 32                 |               | 17.1           | 554.3988            | C₂₀H₄₂D₂O₂Si₂        | 3.2              |
| 33*                |               | 17.8           | 552.3831            | C₂₀H₄₂D₂O₂Si₂        | 3.2              |
| 34                 |               | 18.8           | 548.3549            | C₂₀H₄₂D₂O₂Si₂        | 3.2              |
| 35                 |               | 19.9           | 546.339            | C₂₀H₄₂D₂O₂Si₂        | 2.6              |
| 36                 |               | 20.4           | 546.3389            | C₂₀H₄₂D₂O₂Si₂        | 2.6              |
| 37                 |               | 21.0           | 546.3388            | C₂₀H₄₂D₂O₂Si₂        | 2.3              |
| 38*                | S_V           | 12.9           | 464.3466            | C₂₂H₃₄D₂O₂Si₂        | −0.8             |
| 39*                |               | 14.0           | 461.3253            | C₂₂H₃₄D₂O₂Si₂        | 0.5              |
| 40*                |               | 14.2           | 464.3464            | C₂₂H₃₄D₂O₂Si₂        | −1.2             |
3 | RESULTS AND DISCUSSION

3.1 | Urinary MSTEN metabolites detected by HIR

The employed untargeted metabolite identification approach allows for the sensitive detection of those analytes that retain at least one of the drug’s deuterium atoms during metabolic conversion, as long as the metabolite recovery from the urine is ensured by the applied sample preparation and derivatization technique. Furthermore, the physico-chemical properties of the analyte needs to be compatible with gas chromatographic analyses. In Figure 1, the GC/TC/IRMS results of HPLC fractions collected before and after the administration of deuterated methylstenbolone are shown. Due to the very low natural abundance of deuterium compared with hydrogen, the IRMS is very sensitive to excess deuterium if the instrument is operated under conditions dedicated to the determination of natural HIR.

Especially at the beginning of the excretion study, glucuroconjugated methylstenbolone represents one of the most abundant metabolites together with several hydroxylated metabolites excreted into urine as unconjugated or glucuronidated metabolic products. After approximately 5 days, peaks are still visible in the HIR chromatograms close to the detection limit.

As shown in Figure 1 (lower part, zoom area), the isotope ratio of pregnanediol (PD) seems also to be influenced by the administration of methylstenbolone. This is, however, not attributed to the metabolic conversion of methylstenbolone to pregnanediol but to an artifact of the measurement. During the thermal conversion process, deuterium atoms can be absorbed by the heated aluminum tubing and released when the subsequently eluting compound exiting the GC column is pyrolyzed. Therefore, confirmation of the deuterium content of signals identified in the HIR chromatogram by GC–HRMS under comparable chromatographic conditions is particularly important in order to identify and exclude such analytical artifacts. In the present study, over 40 metabolites were confirmed to contain at least one deuterium atom.

3.2 | MSTEN metabolites suitable for doping control analysis

As the applied derivatization technique (MSTFA in ethyl acetate) during the first step of metabolite detection was not in accordance with

![FIGURE 2](image-url)  
**FIGURE 2** High resolution-parallel reaction monitoring mass spectra of metabolite 5. In the upper part, the deuterated metabolite using the precursor ion at m/z 549.3 is shown, in the lower part the non-deuterated metabolite with precursor ion at m/z 548.3, the deuterium label is present in the A-ring.
the usually applied routine doping control methods, the samples were re-prepared in agreement with routine protocols.

At first, besides changing the derivatization technique, all sample preparation steps were kept including the HPLC fractionation-based target analyte purification. The partitioning of unconjugated steroids was omitted as no long-term metabolites were expected to exist in this fraction. All metabolites found at this stage of the study are summarized in Table 1.

In agreement with literature data on human and especially horse metabolism, the majority of the methylstenbolone metabolites was found to be hydroxylated (24 out of 40 metabolites). Regarding phase-II metabolism, 25 metabolites were excreted glucuronidated and only six metabolites were found simultaneously as both glucurono- and sulfo-conjugated analytes.

Comparing the order of elution and mass spectra, the herein observed metabolites 14 and 18 were assigned to urinary metabolites of methylstenbolone reported by Calvacanti et al. [3, 5] Unfortunately, applying a similar approach concerning the numerous metabolites identified in the horse proved considerably more complex as the gas chromatographic conditions differed substantially and the majority of the metabolites was discussed based on liquid chromatography-mass spectrometry-derived data. [5] With a distinct loss of 103 Da under EI-MS conditions, one metabolite (number 5 in Table 1) showed similar features to the metabolite M1c tentatively characterized as 20-hydroxymethylstenbolone by Choi et al. [5] After close scrutiny of the corresponding mass spectrum of metabolite 5, however, the structure of 20-hydroxymethylstenbolone was not confirmed in the present study as depicted in Figure 2. For both the deuterated and the non-deuterated metabolite, the characteristic fragment at m/z 143.0886 representing a diagnostic D-ring fragment composed of carbons C-15-17 and C-20 plus the O-TMS moiety is still present, which precludes an additional hydroxy group at C-20. [20] A C-18-hydroxylated long-term metabolite as described for metandienone also showing the characteristic loss of 103 Da is not possible here either, as a 18-nor-steroid does not match the found elemental composition of C_{21}H_{32}O_{3}. [21] Taking into account the abundant A-ring fragments at m/z 168.0962 and 195.1196 (respectively at m/z 169.1026 and 196.1261 in the deuterated analogs) and especially the fragment...
at m/z 282.1465 (deuterated at m/z 283.1525) still comprising two TMS-moieties, the hydroxyl group is more likely to be located at C-19 or C-21 (i.e. the methyl group attached to C-2). Especially for 19-hydroxylated steroids, the loss of m/z 103 is well established. With the data to hand, it is not possible to identify unequivocally the position of hydroxylation and further research will be required to clarify this aspect. The metabolite was visible up to 18 days post-administration, but three other metabolites outperformed this result.

3.2.1 Methylstenbolone

The administered compound itself is noted to be particularly resistant concerning metabolic reactions, and taking into account the results of this study the introduction of an additional methyl group into the A-ring of the steroid indeed appears to affect several phase-I-metabolic routes usually observed in steroid metabolism. After preparing 10 mL of urine and HPLC purification, the deuterated glucurono- and

3.2.1 Methylstenbolone

The administered compound itself is noted to be particularly resistant concerning metabolic reactions, and taking into account the results of this study the introduction of an additional methyl group into the A-ring of the steroid indeed appears to affect several phase-I-metabolic routes usually observed in steroid metabolism. After preparing 10 mL of urine and HPLC purification, the deuterated glucurono-

3.2.1 Methylstenbolone

The administered compound itself is noted to be particularly resistant concerning metabolic reactions, and taking into account the results of this study the introduction of an additional methyl group into the A-ring of the steroid indeed appears to affect several phase-I-metabolic routes usually observed in steroid metabolism. After preparing 10 mL of urine and HPLC purification, the deuterated glucurono-

3.2.1 Methylstenbolone

The administered compound itself is noted to be particularly resistant concerning metabolic reactions, and taking into account the results of this study the introduction of an additional methyl group into the A-ring of the steroid indeed appears to affect several phase-I-metabolic routes usually observed in steroid metabolism. After preparing 10 mL of urine and HPLC purification, the deuterated glucurono-
sulfoconjugated MSTEN (metabolites 22 and 39, respectively, Table 1) were visible until the end of the study, i.e. for 29 days after a single oral application. In Figure 3, the extracted ion chromatograms for m/z 461.3253 (± 10 ppm) are depicted. This finding is in good agreement with the results obtained for routine doping control samples yielding AAFs based on the sole presence of (glucurono-conjugated) methylstenbolone. The discrepancy between the herein accomplished detection window and earlier published data might be explained when analyzing the excretion study urine sample data collected after the administration of non-deuterated methylstenbolone. Here, samples were prepared strictly according to routine methods, i.e. without an additional HPLC purification step. Employing high resolution mass spectrometry together with parallel reaction monitoring (PRM), methylstenbolone was detectable for 24 and 25 days as glucuronic acid conjugate and sulfate, respectively, after application of a single oral dose of the drug. Switching to low resolution triple quadrupole mass spectrometry, however, did not allow for mass-resolving co-elutions close to the retention time of methylstenbolone, impeding the unambiguous identification of the target analyte at low urinary concentrations. Depending on the applied precursor/product ion pair, methylstenbolone was only visible for 10 to 16 days after application, regardless of whether the glucuronide or the sulfate was investigated.

### 3.2.2 Novel reduced long term metabolites

The HPLC fraction containing methylstenbolone also furnished two additional peaks of different retention times and different relative intensities but highly comparable mass spectra. These analytes were detected, alongside MSTEN, until the end of the elimination study. The more abundant compound was referred to as Epi-NEW_LTM (Table 1, metabolites 23 and 40) and the less abundant metabolite was termed NEW_LTM (Table 1, metabolites 21 and 38), both detected with a difference in retention time of 1.3 min. The high resolution mass spectrum of Epi-NEW_LTM is shown in Figure 4. The accurate mass of m/z 464.3457 corresponds to the elemental composition of C_{27}H_{48}O_{2}Si_{2} (mass error = 2.7 ppm) and besides the consecutive losses of a methyl radical (15 u) and the TMSOH (90 u), a characteristic loss of C_{3}H_{6}(44 u) is observed. In the publication of Choi et al., methasterone is described as one metabolite of methylstenbolone in the equine. An initial comparison of the mass spectra obtained for methasterone and the new long-term metabolites yielded similar fragments, but the comparison of the methasterone certified reference material and both the metabolites resulted in differing retention times under the described chromatographic conditions.

---

**FIGURE 6** Extracted ion chromatograms obtained employing parallel reaction monitoring (NCE 20 eV) of m/z 462.3 with the transition on m/z 143.0885 +/- 5 ppm of the novel NEW_LTM.
Further investigations on the new metabolites encompassing derivatization with a mixture of MSTFA/ethyl acetate corroborated the presence of two hydroxyl functions. Both metabolites were obtained from methylstenbolone as a result of chemical reduction using LiAlH₄, suggesting the formation of $2\alpha,17\alpha$-dimethyl-$5\alpha$-androst-1-ene-$3\alpha,17\beta$-diol (NEW_LTM) and $2\alpha,17\alpha$-dimethyl-$5\alpha$-androst-1-ene-$3\beta,17\beta$-diol (Epi-NEW_LTM). This hypothesis was confirmed by NMR analysis of the synthetized products; in particular the NOESY contacts of the protons located at the carbons C-3, C-5, C-9, and C-14 on one side of the steroidal skeleton as well as the NOESY contacts between the protons at C-19, C-8, and C-18 on the other side of the ring structures corroborates the stereochemical configuration of the metabolites (Figure 5 and supplemental information). Interestingly, both metabolites were predominantly found in the urinary fraction of glucuronic acid conjugates. This is particularly noteworthy as steroids exhibiting a $3\beta$-OH-functionality preferentially undergo sulfoconjugation. A potential explanation would be the directing of phase-II-metabolism towards position C-17 due to the additional methyl group in position C-2. Another unexpected aspect concerns the detected relative urinary concentrations of the two metabolites. Throughout the entire elimination study, the $3\beta$-epimer (Epi-NEW_LTM) is excreted at higher concentrations than the $3\alpha$-epimer (NEW_LTM). In contrast to this, the endogenously produced androsterone ($3\alpha$-hydroxy-$5\alpha$-androstan-17-one) always prevails over epiaandrosterone ($3\beta$-hydroxy-$5\alpha$-androstan-17-one) in human urine and androsterone is excreted predominantly as glucuronide while epiaandrosterone is exclusively found in the fraction of sulfoconjugated steroids.

In the second excretion study employing non-deuterated methylstenbolone, both metabolites proved to be suitable for sports drug testing. Regarding Epi-NEW_LTM, the peaks were visible for 20 and 23 days (glucuronidated and sulfoconjugated, respectively) and NEW_LTM for 27 and 12 days (glucuronidated and sulfoconjugated, respectively). The results obtained for the glucuronocjugated NEW_LTM are depicted in Figure 6. Despite being excreted at lower urinary concentrations compared with Epi-NEW_LTM (found between 40% and 70% of the higher concentrated epimer), the detectability of this metabolite was found to be superior due to lower interferences originating from the biological matrix.

**FIGURE 7** Full scan high resolution mass spectra obtained for OXO_LTM. Given elemental compositions were calculated within a mass error of ±5 ppm. In the upper part the per-TMS derivative is shown, in the lower part the MSTFA derivative which enabled a preliminary structural elucidation. Further information in the text.
This finding was also corroborated by the third excretion study performed by a different individual, demonstrating good detectability of both NEW_LTM and Epi-NEW_LTM until the end of the study (64 h after administration of non-deuterated MSTEN).

3.2.3 Novel oxygenated long term metabolite

Among the numerous hydroxylated metabolites found in this study, only one candidate showed the potential to prolong the detection time (Table 1, metabolite 15, OXO_LTM) for methylstenbolone administrations. This metabolite, observed only as glucuronide, was also visible until the end of the study employing deuterated MSTEN. The high resolution mass spectrum of the per-TMS derivative (Figure 7, upper part) directly suggested a location of the hydroxyl function at a position other than C-16 as characteristic fragment ions reported for this metabolite in humans such as m/z 218 and m/z 231 were missing. Besides the usual fragment ions derived from demethylation or loss of TMSOH, abundant ions at m/z 314.2041 (C_{20}H_{28}^{2}\text{HOSi}), 244.1265 (C_{15}H_{18}^{2}\text{HOSi}), and especially 221.1332 (C_{13}H_{19}^{2}\text{HOSi}) were found. As all these fragments still contain one deuterium atom and only one TMS-group is present, it is plausible that the steroidal A- and B-rings are included in these structures without being affected by hydroxylation. Further investigations employing MSTFA-derivatization of the hydroxyl functions only suggest the presence of a 16-oxo group. The mass spectra (Figure 7, lower part) of the mono-TMS derivative showed highly characteristic fragment ions at m/z 170.1090, 157.1024, 143.0512, and 130.0782, which were described in the literature as specific for 16-oxo-17-methyl-steroids. A peculiar fragment ion was found at m/z 319.2388, whose molecular formula of C_{20}H_{31}^{2}\text{HOSi} was tentatively attributed to the consecutive eliminations of a methyl radical (15 u), carbon monoxide (28 u) presumably from the steroidal A-ring, and ketene (42 u) from the D-ring. Performing Q-TOF MS/MS experiments using the fragment at m/z 319.2388 as a precursor ion demonstrated the absence of an oxygen atom in the fragments derived from the A-ring of the steroid, supporting the above-mentioned hypothesis regarding structural features of m/z 319.2388. The fragmentation of this metabolite was not further investigated as no reference material was synthesized. Synthesis was postponed after the results of the excretion study employing non-deuterated methylstenbolone showed a significant co-elution overlapping with the new metabolite, limiting its utility in routine doping controls.

4 CONCLUSION

The combination of hydrogen isotope ratio mass spectrometry with high resolution/high accuracy mass spectrometry was successfully applied to the investigation of methylstenbolone metabolism. Even though methylstenbolone appears to be comparably resistant to metabolic enzymes, up to 40 metabolites were identified. The metabolic inertness was reflected by the fact that deuterated MSTEN itself was detected as intact (whilst conjugated) drug until the end of the elimination study. Two novel long-term metabolites NEW_LTM and Epi-NEW_LTW exhibited similar detection windows (27 and 20 days respectively) for sports drug testing purposes, and especially NEW_LTM was found to represent a promising complement for doping controls. As Epi-NEW_LTM showed comparable detection windows, it should also be monitored taking into account the probability of matrix interferences on the one or the other target compound. The third new long-term metabolite OXO_LTM was found to be less suitable for doping control analysis as it was largely indistinguishable from an endogenous substance eluting at the same retention time under the chosen chromatographic conditions.

ACKNOWLEDGMENTS

This project was partly conducted with support of the Manfred-Donike Institute for Doping Analysis (Cologne, Germany) and the Federal Ministry of the Interior, Building and Community (Berlin, Germany).

ORCID

Thomas Piper https://orcid.org/0000-0002-7462-6693
Mario Thevis https://orcid.org/0000-0002-1535-6451

REFERENCES

1. Prohibited List January 2019. World Anti-Doping Agency. https://www.wada-ama.org/en/resources/science-medicine/prohibited-list-documents Accessed 5 August 2019
2. Anti-Doping Testing Figures – Archives. World Anti-Doping Agency. https://www.wada-ama.org/en/resources/laboratories/anti-doping-testing-figures Accessed 5 August 2019
3. Cavalcanti GA, Leal FD, Padilha MC, Aquino Neto FR. Detection of designer steroid methylstenbolone in “nutritional supplement” using gas chromatography and tandem mass spectrometry: elucidation of its urinary metabolites. Steroids. 2013;78(2):228-233.
4. Geldof L, Loutens L, Polet M, et al. Metabolism of methylstenbolone studied with human liver microsomes and the uPA+/+-SCID chimeric mouse model. Biomed Chromatogr. 2014;28(7):974-985.
5. Choi TLS, Wong JKY, Kwok WH, Curl P, Mechle S, Wan TSM. Metabolic study of methylstenbolone in horses using liquid chromatography-high resolution mass spectrometry and gas chromatography-mass spectrometry. J Chromatogr A. 2018;1546:106-118.
6. Thevis M, Piper T, Dib J, et al. Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YK-11 for doping control purposes. Rapid Commun Mass Spectrom. 2017;31(14):1175-1183.
7. Thevis M, Piper T, Horning S, Juchelka D, Schänzer W. Hydrogen isotope ratio mass spectrometry and high-resolution/high-accuracy mass spectrometry in metabolite identification studies: detecting target compounds for sport drug testing. Rapid Commun Mass Spectrom. 2013;27(17):1904-1912.
8. Piper T, Schänzer W, Thevis M. Revisiting the metabolism of 19-nortestosterone using isotope ratio and high-resolution/high accuracy mass spectrometry. J Steroid Biochem Mol Biol. 2016;162:80-91.
9. Piper T, Schänzer W, Thevis M. Genotype-dependent metabolism of exogenous testosterone – new biomarkers result in prolonged detectability. Drug Test Anal. 2016;8:1163-1173.
10. Thevis M. Synthese und Charakterisierung von Glucuronidconjugaten anabol androgener Steroidhormone mittels Gaschromatographie/Massenspektrometrie. Flüssigkeitschromatographie/Massenspektrometrie und kernmagnetischer Resonanz-spektroskopie (PhD Thesis), Shaker Verlag, Aachen, 2002.

11. Schänzer W, Donike M. Metabolism of anabolic steroids in man: synthesis and use of reference substances for identification of anabolic steroid metabolites. Anal Chim Acta. 1993;275:23-48.

12. Piper T, Mareck U, Geyer H, et al. Determination of $^{13}$C/$^{12}$C ratios of endogenous urinary steroids: method validation, reference population and application to doping control purposes. Rapid Commun Mass Spectrom. 2008;22(14):2161-2175.

13. Piper T, Opfermann G, Thevis M, Schänzer W. Determination of $^{13}$C/$^{12}$C ratios of endogenous urinary steroids excreted as sulphoconjugates. Rapid Commun Mass Spectrom. 2010;24(21):3171-3181.

14. Piper T, Thomas A, Thevis M, Saugy M. Investigations on hydrogen isotope ratios of endogenous urinary steroids: reference population based thresholds and proof-of-concept. Drug Test Anal. 2012;4:717-727.

15. Piper T, Emery C, Thomas A, Saugy M, Thevis M. Combination of carbon isotope ratio with hydrogen isotope ratio determinations in sport drug testing. Anal Bioanal Chem. 2013;405(16):5455-5466.

16. Piper T, Thomas A, Baume N, et al. Determination of $^{13}$C/$^{12}$C ratios of endogenous urinary 5-amino-imidazole-4-carboxamide 1β-D-ribofuranoside (AICAR). Rapid Commun Mass Spectrom. 2014;28(11):1194-1202.

17. Donike M, Zimmermann J. Zur Darstellung von Trimethylsilyl- Triethylsilyl- und tert-Butyldimethylsilyl-enoläthern von Ketosteroiden für gas-chromatographische und massenspektrometrische Bestimmungen. J Chrom A. 1980;203(3):483-486.

18. Mareck U, Geyer H, Opfermann G, Thevis M, Schänzer W. Factors influencing the steroid profile in doping control analysis. J Mass Spectrom. 2008;43(7):877-891.

19. Thevis M, Fusshöller G, Schänzer W. Zeranol: doping offence or mycotoxin? A case related study. Drug Test Anal. 2011;3:777-783.

20. Dürbeck HW, Büker I. Studies on anabolic steroids. The mass spectra of 17α-methyl-17β-hydroxy-1,4-androstadien-3-one (Dianabol) and its metabolites. Biomed Mass Spectrom. 1980;7(10):437-445.

21. Schänzer W, Geyer H, Fusshöller G, et al. Mass spectrometric identification and characterization of a new long-term metabolite of metandienone in human urine. Rapid Commun Mass Spectrom. 2006;20(15):2252-2258.

22. Braselton WE Jr, Orr JC, Engel LL. Identification by gas chromatography-mass spectrometry of intermediates in the aromatization of modified C19 steroids by human placental microsomes. Steroids. 1974;24:411-433.

23. Brooks CJW. Some aspects of mass spectrometry in research on steroids. Phil Trans R Soc Lond. 1979;293:53-67.

24. Schänzer W. Metabolism of anabolic androgenic steroids. Clin Chem. 1996;42:1001-1020.

25. Schänzer W, Horning S, Opfermann G, Donike M. Gas chromatography/mass spectrometry identification of long-term excreted metabolites of the anabolic steroid 4-Chloro-1,2-dehydro-17a-methyltestosterone in humans. J Steroid Biochem Mol Biol. 1996;57(5-6):363-376.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.

How to cite this article: Piper T, Fusshöller G, Schänzer W, Lagojda A, Kuehne D, Thevis M. Studies on the in vivo metabolism of methylstenbolone and detection of novel long term metabolites for doping control analysis. Drug Test Anal. 2019;11:1644-1655. https://doi.org/10.1002/dta.2736